| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02965716) | National Cancer Institute (NCI) | 2018-06-05 |
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma (NCT03220009) | National Cancer Institute (NCI) | 2017-11-03 |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (NCT02224781) | National Cancer Institute (NCI) | 2015-09-08 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations (NCT02296112) | Vanderbilt-Ingram Cancer Center | 2015-01-01 |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations (NCT02263898) | Jonsson Comprehensive Cancer Center | 2015-01-01 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery (NCT02166255) | Wake Forest University Health Sciences | 2014-12-01 |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery (NCT02203604) | CINJRegulatory | 2014-11-26 |
| Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma (NCT02107755) | Ohio State University Comprehensive Cancer Center | 2014-09-05 |
| Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery (NCT02120222) | Kari Kendra | 2014-08-22 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic (NCT02094872) | Yale University | 2014-05-01 |
| Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (NCT01970527) | University of Washington | 2014-03-01 |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma (NCT01961115) | Fred Hutchinson Cancer Center | 2013-09-13 |
| Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery (NCT01886235) | Roswell Park Cancer Institute | 2013-09-04 |
| Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma (NCT01898403) | Stanford University | 2013-06-01 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery (NCT01835184) | National Cancer Institute (NCI) | 2013-05-01 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01708941) | National Cancer Institute (NCI) | 2013-03-25 |
| Ipilimumab and Local Radiation for Selected Solid Tumors (NCT01769222) | Stanford University | 2013-02-01 |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery (NCT01701037) | Vanderbilt-Ingram Cancer Center | 2013-01-01 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors (NCT01709435) | National Cancer Institute (NCI) | 2012-11-14 |
| Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma (NCT01703507) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-11-09 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery (NCT01748747) | Mayo Clinic | 2012-10-01 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| FDG-PET in Advanced Melanoma (NCT02236546) | Vanderbilt-Ingram Cancer Center | 2012-05-01 |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma (NCT02507076) | Albert Einstein College of Medicine | 2012-04-01 |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma (NCT01339663) | Fred Hutchinson Cancer Center | 2012-03-01 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib (NCT01519427) | National Cancer Institute (NCI) | 2012-01-01 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery (NCT01533948) | Roswell Park Cancer Institute | 2012-01-01 |
| Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma (NCT01316692) | Vanderbilt-Ingram Cancer Center | 2011-10-01 |
| Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (NCT01303341) | National Cancer Institute (NCI) | 2011-02-18 |
| Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01258855) | National Cancer Institute (NCI) | 2011-01-18 |
| Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery (NCT01328535) | Mayo Clinic | 2011-01-01 |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT01134614) | National Cancer Institute (NCI) | 2010-12-28 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma (NCT01120275) | National Cancer Institute (NCI) | 2010-10-01 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (NCT01217411) | National Cancer Institute (NCI) | 2010-10-01 |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV (NCT01166126) | National Cancer Institute (NCI) | 2010-10-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma (NCT01196416) | National Cancer Institute (NCI) | 2010-08-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma (NCT01103635) | Abramson Cancer Center at Penn Medicine | 2010-02-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma (NCT00945269) | Fred Hutchinson Cancer Center | 2009-07-01 |
| Dinaciclib in Treating Patients With Stage IV Melanoma (NCT00937937) | National Cancer Institute (NCI) | 2009-07-01 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery (NCT00861913) | National Cancer Institute (NCI) | 2009-04-03 |
| MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma (NCT00866177) | National Cancer Institute (NCI) | 2009-03-01 |
| Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma (NCT00871481) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Viral Therapy in Treating Patients With Metastatic Melanoma (NCT00651157) | National Cancer Institute (NCI) | 2008-04-01 |
| Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma (NCT00397982) | National Cancer Institute (NCI) | 2008-01-01 |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma (NCT00553306) | Fred Hutchinson Cancer Center | 2007-09-01 |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery (NCT00281957) | National Cancer Institute (NCI) | 2007-08-01 |
| VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00450255) | National Cancer Institute (NCI) | 2007-06-01 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00470470) | National Cancer Institute (NCI) | 2007-04-01 |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma (NCT00438984) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2006-12-01 |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma (NCT00436605) | National Cancer Institute (NCI) | 2006-12-01 |
| Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma (NCT00387751) | National Cancer Institute (NCI) | 2006-08-01 |
| Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00669019) | National Cancer Institute (NCI) | 2006-07-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT01851408) | National Cancer Institute (NCI) | 2006-04-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT00349206) | National Cancer Institute (NCI) | 2006-04-01 |
| AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (NCT00243061) | National Cancer Institute (NCI) | 2006-01-01 |
| Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00255762) | National Cancer Institute (NCI) | 2005-12-01 |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma (NCT00303836) | National Cancer Institute (NCI) | 2005-11-01 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma (NCT00288041) | National Cancer Institute (NCI) | 2005-10-01 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma (NCT00121225) | National Cancer Institute (NCI) | 2005-09-01 |
| Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery (NCT00217542) | National Cancer Institute (NCI) | 2005-07-01 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00110019) | National Cancer Institute (NCI) | 2005-06-01 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas (NCT00101270) | National Cancer Institute (NCI) | 2005-03-01 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (NCT00655655) | Mayo Clinic | 2004-12-01 |
| Tanespimycin in Treating Patients With Stage III-IV Melanoma (NCT00087386) | National Cancer Institute (NCI) | 2004-06-01 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma (NCT00087373) | National Cancer Institute (NCI) | 2004-06-01 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma (NCT00085189) | University of Southern California | 2004-05-01 |
| Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma (NCT00085306) | Case Comprehensive Cancer Center | 2004-04-01 |
| A Phase II Study of UCN-01 in Metastatic Melanoma (NCT00072189) | National Cancer Institute (NCI) | 2003-11-01 |
| Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma (NCT00072163) | National Cancer Institute (NCI) | 2003-10-01 |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers (NCT00074308) | National Cancer Institute (NCI) | 2003-10-01 |
| Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma (NCT00060333) | Alliance for Clinical Trials in Oncology | 2003-07-01 |
| Tipifarnib in Treating Patients With Metastatic Malignant Melanoma (NCT00060125) | National Cancer Institute (NCI) | 2003-05-01 |
| Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery (NCT01989559) | National Cancer Institute (NCI) | 2002-10-01 |
| Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma (NCT01359956) | National Cancer Institute, Naples | 2002-04-01 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (NCT00039091) | National Cancer Institute (NCI) | 2002-03-01 |
| BMS-247550 in Treating Patients With Stage IV Melanoma (NCT00036764) | National Cancer Institute (NCI) | 2002-02-01 |
| Decitabine in Treating Patients With Advanced Solid Tumors (NCT00030615) | National Cancer Institute (NCI) | 2001-12-01 |
| PS-341 in Treating Patients With Metastatic Malignant Melanoma (NCT00024011) | National Cancer Institute (NCI) | 2001-07-01 |
| Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma (NCT00005949) | National Cancer Institute (NCI) | 2001-03-01 |
| Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma (NCT00006243) | National Cancer Institute (NCI) | 2000-10-01 |
| SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated (NCT00006003) | National Cancer Institute (NCI) | 2000-07-01 |
| Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery (NCT01989572) | National Cancer Institute (NCI) | 2000-02-23 |
| Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma (NCT00019682) | National Cancer Institute (NCI) | 1999-12-01 |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma (NCT00003895) | National Cancer Institute (NCI) | 1999-04-01 |
| Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg (NCT00003789) | National Cancer Institute (NCI) | 1999-03-01 |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma (NCT00003552) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-01-01 |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma (NCT00019448) | National Cancer Institute (NCI) | 1998-09-01 |
| Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma (NCT00003646) | Vical | 1998-08-01 |
| Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma (NCT00003647) | Vical | 1998-07-01 |
| flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer (NCT00019396) | National Cancer Institute (NCI) | 1998-02-01 |
| Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases (NCT02145910) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | |
| Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma (NCT00019890) | National Cancer Institute (NCI) | |